Microcap Ledger Abeona Therapeutics Inc. $ABEO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cleveland, OH
- Fiscal year end
- December 31
- Shares outstanding
- 57,184,017 [10-Q 2026-08-13]
What the company doesAI summary of filing
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for rare genetic diseases. The company's primary product is ZEVASKYN, an FDA-approved autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), which launched commercially in the fourth quarter of 2025. The company also develops a pipeline of adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases using its AIM capsid technology platform. Abeona operates a cGMP manufacturing facility in Cleveland, Ohio, and generates revenue through the commercialization of ZEVASKYN via a network of qualified treatment centers, as well as through licensing agreements and milestone payments from partners. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $20.10M | −$37.27M | −$37.30M | $56.23M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $5.82M | −$71.18M | −$76.33M | $78.44M | [10-K 2026-03-17] |
| FY ended Dec 2024 | — | $63.73M | −$56.02M | $23.36M | [DEF 14A 2026-04-27] |
- Quarterly cash burn
- −$18.65M
- Cash runway Estimate
- ~9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 43,471,030 | [10-Q 2024-11-14] |
| 2025-03-11 | 48,533,798 | [10-K 2025-03-20] |
| 2025-05-09 | 51,156,736 | [10-Q 2025-05-15] |
| 2025-08-08 | 51,278,539 | [10-Q 2025-08-14] |
| 2025-11-07 | 54,191,361 | [10-Q 2025-11-12] |
| 2026-03-11 | 57,049,023 | [10-K 2026-03-17] |
| 2026-05-08 | 56,995,144 | [10-Q 2026-05-13] |
| 2026-08-10 | 57,184,017 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2024-06-12; declared effective 2024-06-20 [S-3 2024-06-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-29 | Seshadri Vishwas | sell | 19,608 | $5.16 | [4 2026-09-29] |
| 2026-09-29 | Vazzano Joseph Walter | sell | 9,191 | $5.16 | [4 2026-09-29] |
| 2026-09-29 | O'Malley Brendan M. | sell | 6,727 | $5.16 | [4 2026-09-29] |
| 2026-09-29 | Vasanthavada Madhav | sell | 4,902 | $5.16 | [4 2026-09-29] |
| 2026-09-01 | Alvino Mark | sell | 15,000 | $5.86 | [4 2026-09-01] |
| 2026-07-21 | Vazzano Joseph Walter | sell | 1,478 | $6.53 | [4 2026-07-22] |
| 2026-07-09 | Vazzano Joseph Walter | sell | 24,880 | $6.96 | [4 2026-07-09] |
| 2026-07-09 | Seshadri Vishwas | sell | 67,971 | $6.96 | [4 2026-07-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-15 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-07-10 | 424B3 | Prospectus or prospectus supplement |
| 2026-06-12 | 8-K | Shareholder vote results |
| 2026-06-12 | 8-K | Director or officer change |
| 2026-06-10 | 8-K | Regulation FD disclosure |
| 2026-06-04 | 8-K | Other events |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 10-Q | Quarterly report |
Alerts for $ABEO
Email me when Abeona Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.